Objective: A recent case series described favorable response of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) to antiprogrammed death-1 (PD-1) immune checkpoint therapy in 4 patients. In this study, we aimed to examine patterns of immunohistochemical (IHC) expression of PD-L1 in SCCOHT and correlate these with available clinical response to immunotherapy.

‍

Method: Clinical and pathological data were available for 4 patients with SCCOHT, including 3 treated with anti-PD-1 immunotherapy. PD-L1 IHC was performed in an additional 4 patients. SMARCA4 genetic testing was completed in all patients. PD-L1 positivity by IHC was quantitatively assessed using either the combined positive score (CPS) or tumor proportion score (TPS).

‍

To continue reading about this article, you can access it here.